We are looking out at the horizon for a huge paralyzing snowstorm that is headed to Washington tonight, little realizing that we are already paralyzed – at least in Congress, a body that cannot seem to move and cannot seem to get anything done.
In the meantime, here is a little bit of what happened this week that was of particular interest:
- Amgen's Prolia (denusomab) Gets CHMP Nod in Europe – Amgen got a positive opinion and now awaits approval in Europe for Prolia which will be indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and in men for bone loss associated with hormone ablation in the course of treatment of prostate cancer. This particular biologic is currently under regulatory review by FDA.
- GSK Publishes Speaking and Consulting Fees Paid to US Docs – In this era of increasing demands for transparency, particularly from some policy makers, GSK announced this week that it would be publishing speaking and consulting fees paid to US doctors. It is an interesting move to get ahead of the curve that raises some further questions however. Such as – why only publish those from the US? And what other pharma companies will follow suit? And, will this placate those who demand greater transparency?
- Twitter List for Those Wanting to Follow Pharma on Twitter – Just a reminder that I opened up a Twitter list that follows the Twitter feeds of pharmaceutical companies on Twitter. If you would like to follow all Pharma Twitter feeds, please join us!
That's it for me this week. It is has been a long hard week and I'm done with it, as I'm also happy to be bidding goodbye to 2009. I will write into next week, but will take a Holiday Hiatus until the New Year after the 23rd.